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Abstract
Background: Tumor induced hypoglycemia (TIH) is a rare clinical entity that can be caused by different
mechanisms such as secretion of various substances, autoimmune disorders, massive tumoral infiltration of liver, and
pituitary or adrenal glands destruction by tumors. Furthermore, any type of neoplasms can cause TIH.
Case presentation: The patient presented with a case of classic biphasic pulmonary blastoma (CBPB) with
hypoglycemia. Chest CT scan showed 2 huge masses in the right hemi-thorax and multiple smaller masses
located in the left hemi-thorax. The patient underwent surgery, and was referred to an oncologist for adjuvant therapy.
Conclusion: CBPB is a rare primary lung tumor with poor prognosis. They are classically large, symptomatic tumors
with lymph node metastasis. Surgical resection at early stages has been more effective than other treatments; however,
there is no standard treatment in unresectable cases. Adjuvant treatments have been temporarily effective.
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Background
Serum glucose levels of under 55 mg/dl, symptoms of
hypoglycemia, and the disappearance of such symptoms
after an increase in the serum’s glucose levels are indica-
tive of hypoglycemia (Whipple’s triad) [1]. TIH is rare
disorder mostly seen in elderly patients with advanced
forms of cancer [2]. It is mainly observed in solid tumors
with mesenchymal and epithelial origins [3].
Pulmonary Blastoma (PB) is mainly seen in young and
middle aged patients with a history of smoking, it is
rarely observed in elderly patients. Clinical symptoms of
PB are hardly definitive or exclusive; they include cough-
ing, chest pain, hemoptysis, fever, pleural effusion, asthe-
nia, anorexia, weight loss and dyspnea [4–7]. In this
report, a case of PB is reported that initially presented
with symptoms of hypoglycemia.
Tumors of PB make up 0.25 to 0.5 % of primary lung tu-
mors [5, 8]. They resemble infant primary lung tissues. The
PB observed in adults is different from that observed in
children from a histologic point of view; adult PB tissue in-
cludes portions of mesenchymal and epithelial tissue [4, 5].
There is no consensus on the histologic origins of PB;
however, it is believed that such tumors originate in primi-
tive multifunctional stromal lung blastoma. Watcher-
Gropinger et al. illustrated that mutations in beta-catenin
and p53 genes had significant roles in the appearance of
these tumors [5].
In children, PB is similar to infantile rhabdomyosar-
coma from an immunologic and cytogenetic perspective,
suggesting that partial chromosome deletion may have a
role in PB. However, there is no overall agreement re-
garding the cause of pulmonary blastoma and more in-
vestigation is needed [5].
In diagnosing PB, CX-Ray and CT scan can be used to
observe lung masses. These masses may exhibit necrosis
and parts of them can be enhanced using contrast [5].
Case Presentation
A 58-year-old male with history of weakness and malaise
for 18 months was referred to Shariati hospital. In the
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initial work up, frequent episodes of hypoglycemia and
elevated erythrocyte sedimentation rate were detected
(Table 1). Chest CT scan showed 2 huge masses located in
right hemi-thorax and multiple smaller masses located in
the left hemi-thorax (Fig. 1a, b). The histopathological re-
sult of core needle biopsy before surgery was in favor of a
solitary fibrous tumor. Right posterolateral thoracotomy
and resection of 2 huge masses were performed and Per-
manent pathologic examination confirmed the diagnosis.
After surgery, symptoms of hypoglycemia resolved.
In spite of recommendations, the patient did not come
back for resection of the left hemithorax masses. How-
ever, the patient visited our clinic due to hypoglycemic
symptoms and dyspnea 2 years later. Imaging study re-
vealed multiple bilateral parenchymal and pleural-based
nodules (Fig. 1c, d). He underwent left posterolateral
thoracotomy again and 45 masses were excised. Perman-
ent pathology report revealed a pulmonary blastoma
(Figs. 2, 3). His symptoms partially resolved and he was
referred to an oncologist for adjuvant therapy after
32 days stay in ICU and surgical ward.
Afterwards the patient’s history and laboratory profiles
were reviewed and histology of the right sided tumor
was reassessed. It was determined that the correct diag-
nosis for the right hemi-thorax tumor was PB, similar to
the diagnosis for the left hemi thorax tumor.
Tumors causing hypoglycemia can be classified ac-
cording to their mechanism of action. The first group
acts by secreting insulin, Insulinoma is the most
prevalent example of this group. The second group acts
through secreting insulin-like growth factor. The third
group consists of multiple myeloma, lymphoma, and
leukemia. The fourth group consists of metastatic neo-
plasms [1].
Tumors secreting insulin-like growth factor are also
known as non-islet cell tumor hypoglycemia (NICTH);
they can cause hypoglycemia through multiple mecha-
nisms [1]. They mostly originate in lungs, the digestive
system, adrenal gland, the pancreas, or the ovaries [9].
These groups of tumors frequently appear in the fifth or
sixth decade of life. The average length of symptoms can
range from a few weeks to a few months [7]. This pa-
tient was in sixth decade of life, when experienced an in-
crease in insulin-like growth factor. Patient’s tumor was
relatively large in all stages.
Hypoglycemia in these patients is mostly episodic.
Each episode happens as a result of hunger, rather than
eating food. Hypoglycemia in this patient was episodic
and a result of hunger as well [7].
The possible pathophysiological causes of hypoglycemia
include increases in secretion of IGF, invasion of the liver
by a tumor, disruption of counter regulatory mechanisms
as a result of adrenal blockage, increase on consumption
of glucose by the tumor, and antibodies against insulin
and insulin receptors [1, 9]. In this patient, higher secre-
tions of IGF and an increase in glucose consumption due
to the tumor were the causes of hypoglycemia.
Tumors that emit IGF2 (NICTHs) are diagnosed when
the following are observed: low serum glucose levels
during acute attacks, low levels of insulin and C-peptide
in the serum, low levels of growth hormone and the
insulin-like growth factor-1, normal or high levels of the
insulin-like growth factor-2, and higher relative levels of
insulin-like growth factor 2 compared to its counterpart
similar to insulin-like growth factor 1 [1, 2, 10].
From a biochemical point of view, TIH is widely ac-
companied by hyperketonemia (<300 micromole/L). In
53 % of cases with NICTH hypokalemia is observed [7].
This patient had hypokalemia as well. Hypokalemia is
caused by the insulin like activities of the insulin-like
growth factor 2 (IGF2).
In all patients with epithelial or mesenchymal tumors
that exhibit neuro psychiatric symptoms, NICTH should
be considered [7]. Our patient reported weakness, tired-
ness, and excessive sweating. Furthermore, hypoglycemia
was observed in the lab report.
NICTHs have a large domain. 40 % of them have mesen-
chymal origin; these include mesothelioma, hemangioperi-
cytoma, and sarcomas. Another 40 % have epithelial origin;
these include hepatocellular and lung sarcomas. The ori-
gins of the remaining 20 % of tumors are unknown [7].
PB is a distinct form of carcinosarcoma which was de-
fined by Adluri [8]. It can appear as a parenchymal
Table 1 Laboratory parameters showed in first and last admission







WBC 7260 8130 4000-10000 cumm
Hb 9.5 15.6 14–18 g/dl
Plt 405000 283000 150000–400000 cumm
ESR 116 77 0–20 mm/h
MCV 80 84 80–100 fl
BUN 16 12 7–21 mg/dl
Cr 1 0.9 0.7–1.4 mg/dl
BS random 62–59 42–30 mg/dl
Na 147 145 135–145 Meq/l
K 3.7 4 3.6–5.2 Meq/l
Ca 9.1 8 8.6–10.3 mg/dl
LDH 498 584 Up to 480 IU/l
C-peptide 0.05> 0.1 0.7–1.9 ng/ml
Cortisol (8 am) 14.5 - 5–23 micg/dl
IGF-1 33 - 22–197 ng/ml
Insulin 3.9 5.7 0.7–20 MIU/ml
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tumor or sub pleural nodules with pulmonary effusion
[11]. In this report, the patient had multiple bilateral
parenchymal and subpleural tumors.
PBs are divided into 3 groups according to their tissue
make up. The first group is the monophasic group (good
differentiation) which has an epithelial composition. The
second group is the classic biphasic group, which consists
of both epithelial and mesenchymal components (CBPB).
The third group is the pleuropulmonary blastoma; they
are tumors specific to childhood and only have mesenchy-
mal tissue [12, 13]. This patient’s tumor was a CBPB.
Symptoms of CBPB are similar to symptoms of lower
respiratory system infection [13]. In second visit, the pa-
tient’s chief complaint was dyspnea. However, episodic
hypoglycemia was a secondary complaint as well. PB can
invade the heart, the diaphragm, and the liver [7]. CX
Fig. 1 Contrast enhanced axial CT scan of the patient before a, b and after c, d surgery. There is a large solid mass in lower zone of right hemithorax
with complete collapse of right lower lobe and cardiac displacement to left a. There is also an 18 × 15 mm parenchymal nodule in left upper lobe.
Several other smaller nodules are found in this exam (not shown) in the rest of left lung. Two years after resection of the large mass in basal aspect of
right hemithorax, there are numerous bilateral parenchymal and pleural-based nodules and masses with maximum size of 42 × 40 mm c, d
a b 
c d
Fig. 2 a: A biphasic tumor which composed of a mixture of malignant epithelial and stromal component (h&e. magnification × 40). b: The epithelial
component was consisted of tubular and glandular structures, formed by columnar and cuboidal cells (h&e. magnification × 100). c: The stroma in
some foci differentiated to cartilage (h&e. magnification × 40). d: The stroma of tumor was consisted of loose undifferentiated mesenchyme and areas
with blastomatous appearance (h&e. magnification × 400)
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Ray and CT scan can assist in diagnosis. Functional im-
aging methods are inefficient at recognizing relapse and
metastasis in NICTH [7]. Immunohistochemistry has a
vital role in recognizing CBPB [9, 13]. Despite the new
techniques for diagnosis, correct recognition before sur-
gery is still difficult [4, 5, 7, 8, 12]. In this patient, accur-
ate diagnosis was reached after the second surgery.
In both surgeries, the majority of the tumor was re-
moved during the operation, resulting in the disappear-
ance of hypoglycemia. Approximately 2 years after the
first operation, the symptoms returned. However, the re-
moval of the tumor during the second surgery resulted in
the disappearance of symptoms again. The hypoglycemia
was accompanied by low serum insulin, IGF-1, and C-
peptide levels; Therefore, it may have been caused by in-
creased glucose consumption of the large tumor and ex-
cretion of IGF-2 by the tumor. However, it is not possible
to confirm this hypothesis at this time, as there were no
methods available to measure blood IGF-2 levels.
Medical treatments for NICTH include diazoxide, octreo-
tide, glucagon infusion, steroids, and recombinant growth
hormone. Glucose tablets can be prescribed as well [9].
However, the definitive treatment is surgery [4, 5, 12].
Surgical treatments for NICTH include complete re-
moval of the tumor, or debulking accompanied with
radiotherapy and chemotherapy [5, 7, 10].
Glucocorticoids are the most effective method of
long term management [1, 7]. The hypoglycemia can
be controlled through chemotherapy, radiotherapy,
and embolization with various success rates [9]. PBs
are fast growing tumors with poor prognosis [4, 6].
Factors that illustrate the poor prognosis in adult PBs in-
clude relapse, metastatic illness, larger than 5 cm tumor,
and lymphatic system involvement [6, 7, 13].
The effectiveness of chemotherapy and radiotherapy is
unknown. However, due to the metastatic nature of this
patient’s illness, he was referred for adjuvant treatment.
In previous reports chemotherapy has been recom-
mended in cases of metastasis [4, 7]. Overall, studies re-
garding the effects of chemotherapy and radiotherapy
are scarce, but some researchers have reported the ef-
fectiveness of using platinum [13].
In locally advanced tumors, mediastinal lymph node
involvement, or metastatic cases chemotherapy / radio-
therapy can be used. Chemotherapy’s effect on treatment
is limited [3, 4].
In our patient, 40 months have passed since the begin-
ning of illness. After 2 surgeries the tumor is currently
under control with the help of chemotherapy.
Conclusion
In this patient, symptoms of hypoglycemia disappeared
after 2 tumor debulking surgeries. Furthermore, serum in-
sulin, C-peptide, and IGF1 were normal after the oper-
ation. Despite the fact that it was not possible to measure
IGF2 levels at our center, it is possible to assume with
some measure of certainty that the cause of hypoglycemia
in this case was the patient’s tumor. However, absolute
certainty would require further biochemical and molecular
studies.
It has become increasingly apparent in the recent years,
that almost any type of neoplasm can cause hypoglycemia
by a number of mechanisms.
NICTH is a rare cause of hypoglycemia usually seen in
large mesenchymal tumors. CBPB is characterized by
both epithelial and mesenchymal malignant components.
Diagnosis of CBPB with core needle biopsy is difficult. If
histopathologic examinations revealed the diagnosis of
Fig. 3 a-b: CK (AE1/AE3), and TTF-1 are positive in epithelial component. c-e: Vimentin, CD34 and bcl-2 are positive in mesenchymal component.
f: β-catenin is expressed diffusely in both epithelial and mesenchymal elements
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solitary fibrous tumor in a patient with multiple lung tu-
mors not compatible with patient’s clinical and imaging
findings, repeated histopathological evaluation is recom-
mended. The principal treatment for CBPB is surgery.
Chemotherapy and radiotherapy have been tried for ad-
vanced tumors.
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